Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742394 | 0.86 | SIGMAR1 (0.63) | SMN1; SMN2SMYD3SIGMAR1KMT2ARAB9A | |
| SCHEMBL16420963 | 0.84 | SIGMAR1 (0.62) | SMN1; SMN2SMYD3SIGMAR1MEN1KMT2A | |
| SCHEMBL12819735 | 0.84 | SMYD3 (0.56) | SMN1; SMN2SMYD3SIGMAR1MEN1KMT2A | |
| SCHEMBL19739051 | 0.78 | SIGMAR1 (0.70) | SMN1; SMN2SMYD3SIGMAR1ATM | |
| SCHEMBL4436172 | 0.77 | MEN1 (0.50) | SMN1; SMN2SMYD3SIGMAR1MEN1KMT2A | |
| SCHEMBL8725935 | 0.77 | ACKR3 (0.50) | SMN1; SMN2SIGMAR1MEN1KMT2AACKR3 | |
| Hydrochloric Acid SCHEMBL4960761 | 0.76 | KMT2A (0.52) | SMN1; SMN2SMYD3SIGMAR1MEN1KMT2A | |
| SCHEMBL15279721 | 0.76 | ACKR3 (0.52) | SMN1; SMN2SMYD3SIGMAR1KMT2AEPHX1 | |
| SCHEMBL13673408 | 0.76 | ACKR3 (0.49) | SMN1; SMN2SMYD3SIGMAR1LMNAACKR3 | |
| SCHEMBL13621162 | 0.76 | ALDH1A1 (0.62) | SMN1; SMN2SIGMAR1KMT2AEPHX1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SMN1; SMN2 646/4885SMYD3 1177/4885SIGMAR1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.